Study to assess the plasma concentration of tolebrutinib given as a tablet to adult participants with mild hepatic impairment compared to participants with normal hepatic function

Trial Identifier: POP16398
Sponsor: Sanofi
Start Date: March 2022
Primary Completion Date: May 2022
Study Completion Date: May 2022
Condition: Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
UNITED STATES, Florida Miami, Florida, UNITED STATES, 33014
UNITED STATES, Minnesota St. Paul, Minnesota, UNITED STATES, 55114